+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular Diseases, Diabetes), Type (Disposable, Reusable), Route of Administration (Subcutaneous, Intramuscular), End-user (Hospital) and Region - Forecast to 2025

  • PDF Icon

    Report

  • 177 Pages
  • December 2020
  • Region: Global
  • Markets and Markets
  • ID: 5214995
Description Jump to:

The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices.

The rheumatoid arthritis segment accounted for the largest share of the autoinjectors market in 2020

Based on therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapies (cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest market share of autoinjectors market. The large share of this segment is mainly due to the high prevalence of rheumatoid arthritis.

The subcutaneous segment is projected to grow at the highest CAGR during the forecast period

Based on route of administration, the autoinjectors market is segmented into intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anemia, and cancer. The subcutaneous segment is projected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.

North America accounted for the largest share of the autoinjectors market in 2020

The autoinjectors market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Latin America, and the Middle East & Africa. North America was the largest regional market for autoinjectors. Growth in the North American market is majorly driven by factors such as the rising incidence of anaphylaxis and the presence of favorable reimbursements. Moreover, the US and Canada are developed economies with high awareness and adoption rates for advanced devices such as autoinjectors, which is beneficial for market growth. Furthermore, other micro-economic indicators such as rising healthcare expenditures, high affordability rate, and the improving regulatory scenario are also major factors contributing to market growth.

Research Coverage

The market study covers the autoinjectors market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by therapy, type, route of administration, end users and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Some of the key players in the autoinjectors market are AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany), Meridian Medical Technologies, Inc. (US), Roche Diagnostics (Switzerland), Bespak (UK), Bayer (Germany), SHL Medical (Switzerland), Haselmeier (Switzerland), Owen Mumford (UK), Ravimed (Poland), Medeca Pharma AB (Sweden), Cambridge Consultants Ltd. (UK), Flex (US), SMC Ltd. (US), and Promius Pharma (US). The study includes an in-depth competitive analysis of these key players in the autoinjectors market, along with their company profiles, recent developments, and key market strategies.

Break-up of Primaries


  • By Company: Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
  • By Designation: C-level Executives: 25%, Directors: 55%, and Others: 20%
  • By Region: North America: 40%, Europe: 25%, APAC: 20%, LATAM: 10%, and MEA: 5%

Key Benefits of Buying the Report

The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the autoinjectors market and its subsegments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders understand the pulse of the market and provide information on key market drivers, restraints, opportunities and challenges.


Table of Contents

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition & Scope
1.3 Markets Covered
Figure 1 Autoinjectors Market Segmentation
1.4 Years Considered for the Study
1.5 Currency
1.6 Limitations
1.7 Stakeholders
1.8 Summary of Changes
2 Research Methodology
2.1 Research Approach
Figure 2 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Breakdown of Primaries
Figure 4 Breakdown of Primary Interviews (Supply Side): by Company Type, Designation, and Region
Figure 5 Breakdown of Primary Interviews (Demand Side): by End-user, Designation, and Region
2.2 Market Size Estimation
Figure 6 Market Size Estimation: Revenue Share Analysis (2019)
Figure 7 Market Size Estimation: Revenue Share Analysis (2019)
Figure 8 Supply-Side Analysis: Autoinjectors Market (2019)
Figure 9 CAGR Projections: Supply-Side Analysis of the Autoinjectors Market (2019)
Figure 10 CAGR Projections from the Analysis of Drivers, Restraints, Opportunities, and Challenges of the Autoinjectors Market (2020-2025)
2.3 Market Breakdown & Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study
2.6 COVID-19 Health Assessment
2.7 COVID-19 Economic Assessment
2.8 Assessment of the Impact of COVID-19 on the Economic Scenario
Figure 12 Criteria Impacting the Global Economy
Figure 13 Recovery Scenario of the Global Economy
3 Executive Summary
Figure 14 Autoinjectors Market, by Therapy, 2020 Vs. 2025 (USD Million)
Figure 15 Autoinjectors Market, by Type, 2020 Vs. 2025 (USD Million)
Figure 16 Autoinjectors Market, by Route of Administration, 2020 Vs. 2025 (USD Million)
Figure 17 Autoinjectors Market, by End-user, 2020 Vs. 2025 (USD Million)
Figure 18 Geographical Snapshot of the Autoinjectors Market
4 Premium Insights
4.1 Autoinjectors Market Overview
Figure 19 Growing Prevalence of Targeted Therapies and Rising Preference for Self-Administration of Drugs to Drive Market Growth
4.2 Asia-Pacific: Autoinjectors Market, by Therapy and Country (2020)
Figure 20 Rheumatoid Arthritis Segment to Account for the Largest Share of the APAC Market in 2020
4.3 Autoinjectors Market, by Region, 2020-2025
Figure 21 North America Will Continue to Dominate the Autoinjectors Market in the Forecast Period
4.4 Autoinjectors Market: Developed Vs. Developing Markets
Figure 22 Developing Markets to Register Higher Growth During the Forecast Period
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 23 Autoinjectors Market: Drivers, Restraints, Opportunities, & Challenges
5.2.1 Drivers
5.2.1.1 Growing Prevalence of Targeted Therapies
Figure 24 China: Total Diabetic Population from 2010 to 2045
5.2.1.2 Rising Incidence of Anaphylaxis
5.2.1.3 Increasing Number of Regulatory Approvals
Table 1 Recent Approvals of Autoinjector Devices Across the Globe
5.2.1.4 Availability of Generic Versions of Autoinjectors
5.2.1.5 Favorable Reimbursements and Government Support
5.2.1.6 Ease of Use Increasing the Preference for Self-Administration
5.2.2 Restraints
5.2.2.1 Alternative Drug Delivery Modes
5.2.2.2 Research, Development, and Launch of Oral Diabetic Agents and Oral Insulin
5.2.2.3 Development of Nasal Epinephrine Sprays
5.2.3 Opportunities
5.2.3.1 Patent Expiry of Biologics to Drive the Demand for Biosimilars
Table 2 Patent Expiry of Key Biologics
5.2.3.2 Need to Limit Patient Visits and Physical Contact
5.2.4 Challenges
5.2.4.1 Development of Autoinjectors for Multiple Drug Viscosities
5.2.4.2 Lack of Proper Training for Using Autoinjectors
5.3 COVID-19 Impact on the Autoinjectors Market
5.4 Average Selling Price Trends
Table 3 Average Selling Price of Epinephrine Autoinjectors, by Region, 2015 Vs. 2020
5.5 Value Chain Analysis
Figure 25 Autoinjectors Market: Value Chain Analysis (2019)
5.6 Ecosystem Analysis
Figure 26 Ecosystem: Autoinjectors Market (2019)
6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Advancements in Autoinjector Design
6.2.2 Wearable Autoinjectors
6.2.3 Connected Autoinjector Devices
7 Autoinjectors Market, by Therapy
7.1 Introduction
Table 4 Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
7.2 Rheumatoid Arthritis
7.2.1 Increasing Incidence of Ra Has Boosted the Adoption of Autoinjectors
Table 5 Autoinjectors Market for Rheumatoid Arthritis, by Country, 2018-2025 (USD Million)
7.3 Diabetes
7.3.1 Large Patient Population to Stimulate the Demand for Autoinjectors During the Forecast Period
Figure 27 Diabetic Population: Top Countries/Territories (20-79 Years), 2019 Vs. 2030 Vs. 2045
Table 6 Autoinjectors Market for Diabetes, by Country, 2018-2025 (USD Million)
7.4 Multiple Sclerosis
7.4.1 Influx of Generics is Expected to Negatively Impact Market Growth During the Forecast Period
Figure 28 Number of People with Ms (Per 100,000) - Who Regions
Table 7 Autoinjectors Market for Multiple Sclerosis, by Country, 2018-2025 (USD Million)
7.5 Anaphylaxis
7.5.1 Increasing Prevalence of Food Allergies to Drive the Uptake of Autoinjectors
Table 8 Autoinjectors Market for Anaphylaxis, by Country, 2018-2025 (USD Million)
7.6 Other Therapies
Table 9 Autoinjectors Market for Other Therapies, by Country, 2018-2025 (USD Million)
7.7 Impact of COVID-19 on the Therapeutic Applications of Autoinjectors
8 Autoinjectors Market, by Type
8.1 Introduction
Table 10 Comparison of Disposable & Reusable Autoinjectors
Table 11 Autoinjectors Market, by Type, 2018-2025 (USD Million)
8.2 Disposable Autoinjectors
8.2.1 Disposable Autoinjectors are Convenient for Patients with Reduced Dexterity or Visual Impairments
Table 12 Disposable Autoinjectors Market, by Country, 2018-2025 (USD Million)
8.3 Reusable Autoinjectors
8.3.1 Reusable Autoinjectors are More Economical as Compared to Disposable Autoinjectors
Table 13 Reusable Autoinjectors Market, by Country, 2018-2025 (USD Million)
9 Autoinjectors Market, by Route of Administration
9.1 Introduction
Table 14 Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
9.2 Subcutaneous
9.2.1 Growing Number of Product Approvals by Regulatory Bodies Will Support the Growth of this Market Segment
Table 15 Subcutaneous Autoinjectors, by Country, 2018-2025 (USD Million)
9.3 Intramuscular
9.3.1 Intramuscular Route of Administration Enables Medication to be Absorbed Quickly - A Key Factor Driving Market Growth
Table 16 Examples of Intramuscular Autoinjectors
Table 17 Intramuscular Autoinjectors Market, by Country, 2018-2025 (USD Million)
10 Autoinjectors Market, by End-user
10.1 Introduction
Table 18 Autoinjectors Market, by End-user, 2018-2025 (USD Million)
10.2 Home Care Settings
10.2.1 Home Care Therapies are Cost-Effective Compared to Treatments in Hospitals - A Key Factor Driving Market Growth
Table 19 Autoinjectors Market for Home Care Settings, by Country, 2018-2025 (USD Million)
10.3 Hospitals & Clinics
10.3.1 High Usage of Autoinjectors in Emergency Cases in Hospitals & Clinics Will Drive Market Growth
Table 20 Autoinjectors Market for Hospitals & Clinics, by Country, 2018-2025 (USD Million)
10.4 Ambulatory Care Settings
10.4.1 Increasing Number of Patients in Ambulatory Care Settings to Drive the Demand for Autoinjectors
Table 21 Autoinjectors Market for Ambulatory Care Settings, by Country, 2018-2025 (USD Million)
11 Autoinjectors Market, by Region
11.1 Regional COVID-19 Impact: Summary
11.2 Introduction
Figure 29 Autoinjectors Market: Geographic Growth Opportunities
Table 22 Autoinjectors Market, by Region, 2018-2025 (USD Million)
11.3 North America
Figure 30 North America: Autoinjectors Market Snapshot
Table 23 North America: Autoinjectors Market, by Country, 2018-2025 (USD Million)
Table 24 North America: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 25 North America: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 26 North America: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 27 North America: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.3.1 US
11.3.1.1 The US is the Largest Market for Autoinjectors in North America
Table 28 Autoinjectors Approved by the FDA, 2017-2019
Table 29 US: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 30 US: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 31 US: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 32 US: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.3.2 Canada
11.3.2.1 Rising Prevalence of Chronic Diseases to Drive the Market Growth
Table 33 Canada: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 34 Canada: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 35 Canada: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 36 Canada: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.4 Europe
Figure 31 Europe: Autoinjectors Market Snapshot
Table 37 Europe: Autoinjectors Market, by Country, 2018-2025 (USD Million)
Table 38 Europe: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 39 Europe: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 40 Europe: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 41 Europe: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.4.1 Germany
11.4.1.1 Germany is the Largest Market for Autoinjectors in Europe
Table 42 Germany: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 43 Germany: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 44 Germany: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 45 Germany: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.4.2 UK
11.4.2.1 The UK Has the Highest Rate of Allergic Conditions Globally - A Key Factor Expected to Boost the Market Growth
Table 46 UK: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 47 UK: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 48 UK: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 49 UK: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.4.3 France
11.4.3.1 Rising Geriatric Population to Support Market Growth
Table 50 France: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 51 France: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 52 France: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 53 France: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.4.4 Italy
11.4.4.1 Improving Economic Conditions and Rising Per Capita Income to Propel Market Growth
Table 54 Italy: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 55 Italy: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 56 Italy: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 57 Italy: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.4.5 Spain
11.4.5.1 Favorable Reimbursement Scenario Coupled with the Rising Prevalence of Chronic Diseases to Support Market Growth
Table 58 Spain: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 59 Spain: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 60 Spain: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 61 Spain: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.4.6 Rest of Europe
Table 62 Roe: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 63 Roe: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 64 Roe: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 65 Roe: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.5 Asia-Pacific
Figure 32 Asia-Pacific: Autoinjectors Market Snapshot
Table 66 Asia-Pacific: Autoinjectors Market, by Country, 2018-2025 (USD Million)
Table 67 Asia-Pacific: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 68 Asia-Pacific: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 69 Asia-Pacific: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 70 Asia-Pacific: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.5.1 Japan
11.5.1.1 High Adoption of Autoinjectors and Approval of Several Injectable Devices to Boost the Market Growth
Table 71 Japan: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 72 Japan: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 73 Japan: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 74 Japan: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.5.2 China
11.5.2.1 Food Allergies and Anaphylaxis Have Become a Major Public Health Burden in China
Table 75 China: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 76 China: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 77 China: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 78 China: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.5.3 India
11.5.3.1 Increasing Burden of Chronic Diseases Such as Diabetes and CVD is Expected to Drive the Demand for Autoinjectors in India
Table 79 India: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 80 India: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 81 India: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 82 India: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.5.4 RoAPAC
Table 83 RoAPAC: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 84 RoAPAC: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 85 RoAPAC: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 86 RoAPAC: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.6 Latin America
11.6.1 Rising Elderly Population in Countries Such as Brazil and Mexico to Support Market Growth
Table 87 Latin America: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 88 Latin America: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 89 Latin America: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 90 Latin America: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
11.7 Middle East & Africa
11.7.1 Implementation of Favorable Reforms in Africa as Well as Middle Eastern Countries to Drive Market Growth
Table 91 MEA: Autoinjectors Market, by Therapy, 2018-2025 (USD Million)
Table 92 MEA: Autoinjectors Market, by Type, 2018-2025 (USD Million)
Table 93 MEA: Autoinjectors Market, by Route of Administration, 2018-2025 (USD Million)
Table 94 MEA: Autoinjectors Market, by End-user, 2018-2025 (USD Million)
12 Company Evaluation Matrix
12.1 Market Share Analysis
Figure 33 Autoinjectors Market Share Analysis, by Key Player, 2019
12.2 Vendor Dive
12.2.1 Stars
12.2.2 Emerging Leaders
12.2.3 Pervasive Players
12.2.4 Emerging Companies
Figure 34 Autoinjectors Market: Competitive Leadership Mapping, 2019
12.3 Competitive Leadership Mapping for Small & Medium-Sized Enterprises (SMEs)/Startups
12.3.1 Progressive Companies
12.3.2 Starting Blocks
12.3.3 Responsive Companies
12.3.4 Dynamic Companies
Figure 35 Autoinjectors Market: Competitive Leadership Mapping for Start-Ups, 2019
13 Competitive Landscape
13.1 Introduction
Figure 36 Key Developments in the Autoinjectors Market
Figure 37 Growth Strategy Matrix
13.2 Product Portfolio Matrix
13.2.1 Therapy
13.3 Autoinjectors Market: Geographical Assessment
Figure 38 Geographic Assessment of Key Players in the Autoinjectors Market (2019)
13.4 Autoinjectors Market: R&D Expenditure
Figure 39 R&D Expenditure of Key Players in the Autoinjectors Market (2019)
13.5 Competitive Situations and Trends
13.5.1 Product Launches & Approvals
Table 95 Product Launches & Approvals (2018-2020)
13.5.2 Partnerships, Collaborations, and Agreements
Table 96 Partnerships, Collaborations, and Agreements (2018-2020)
13.5.3 Acquisitions
Table 97 Acquisitions (2020)
13.5.4 Expansions
Table 98 Expansions (2018-2020)
13.5.5 Other Developments
Table 99 Other Developments (2019-2020)
14 Company Profiles
(Business Overview, Products Offered, Recent Developments, Analyst's View, and Strategic Overview)*
14.1 Abbvie Inc.
Figure 40 Abbvie Inc.: Company Snapshot (2019)
14.2 Amgen
Figure 41 Amgen: Company Snapshot (2019)
14.3 Eli Lilly and Company
Figure 42 Eli Lilly and Company: Company Snapshot (2019)
14.4 Mylan
Figure 43 Mylan: Company Snapshot (2019)
14.5 Ypsomed
Figure 44 Ypsomed: Company Snapshot (2019)
14.6 Becton, Dickinson and Company
Figure 45 BD: Company Snapshot (2019)
14.7 GlaxoSmithKline plc
Figure 46 GlaxoSmithKline plc: Company Snapshot (2019)
14.8 Johnson & Johnson (J&J)
Figure 47 Johnson & Johnson: Company Snapshot (2019)
14.9 Teva Pharmaceutical Industries
Figure 48 Teva Pharmaceutical Industries: Company Snapshot (2019)
14.10 Antares Pharma, Inc.
Figure 49 Antares Pharma: Company Snapshot (2019)
14.11 Merck KGaA
Figure 50 Merck KGaA: Company Snapshot (2019)
14.12 Meridian Medical Technologies, Inc. (A Pfizer Company)
Figure 51 Pfizer: Company Snapshot (2019)
14.13 F. Hoffmann-La Roche
Figure 52 F. Hoffmann-La Roche Ltd.: Company Snapshot (2019)
14.14 Bespak
Figure 53 Consort Medical plc: Company Snapshot (2019)
14.15 Bayer AG
Figure 54 Bayer AG: Company Snapshot (2019)
14.16 Bristol-Myers Squibb Company
Figure 55 Bristol-Myers Squibb Company: Company Snapshot (2019)
14.17 SHL Medical
14.18 Haselmeier
14.19 Owen Mumford
14.20 Ravimed
14.21 Medeca Pharma AB
*Details on Business Overview, Products Offered, Recent Developments, Analyst's View, and Strategic Overview Might Not be Captured in Case of Unlisted Companies
15 Appendix
15.1 Insights from Industry Experts
15.2 Discussion Guide
15.3 Knowledge Store: The Subscription Portal
15.4 Available Customizations

Executive Summary

Companies Mentioned

  • Abbvie Inc.
  • Amgen
  • Antares Pharma, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bespak
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • GlaxoSmithKline plc
  • Haselmeier
  • Johnson & Johnson (J&J)
  • Medeca Pharma AB
  • Merck KGaA
  • Meridian Medical Technologies, Inc. (A Pfizer Company)
  • Mylan
  • Owen Mumford
  • Ravimed
  • SHL Medical
  • Teva Pharmaceutical Industries
  • Ypsomed

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages177
PublishedDecember 2020
Forecast Period2020 - 2025
Estimated Market Value ( USD ) in 2020 $ 46 billion
Forecasted Market Value ( USD ) by 2025 $ 104.9 billion
Compound Annual Growth Rate17.9%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Autoinjectors - Global Strategic Business Report - Product Image

Autoinjectors - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Autoinjectors Global Market Report 2024 - Product Image

Autoinjectors Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Global Autoinjector Market Report and Forecast 2023-2031 - Product Image

Global Autoinjector Market Report and Forecast 2023-2031

  • Report
  • 140 Pages
  • Global
From
Global Autoinjector Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global Autoinjector Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 184 Pages
  • Global
From
Global Epinephrine Autoinjector Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global Epinephrine Autoinjector Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.